JPMorgan Downgrades Alnylam Pharmaceuticals (ALNY) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Alnylam Pharmaceuticals Reports Second Quarter 2015 Financial Results and Highlights Recent Period Activities
August 6, 2015 4:00 PM EDTAdvanced Pipeline of Seven Investigational Clinical Programs and Presented Positive Clinical Results for Three: Patisiran for Familial Amyloidotic Polyneuropathy (FAP), ALN-AT3 for Hemophilia, and ALN-CC5 for Complement-Mediated Diseases
In Addition to Upcoming Presentation of ALN-PCSsc Clinical Results, Announces New Plan to Present Initial Clinical Data for ALN-AS1 Porphyria Program at Medical Meeting in September and Provides Update on Revusiran Phase 2 Open-Label Extension Study
Maintained Strong Balance Sheet with $1.40 Billion in Cash and Remains On Track to End 2015 with Greater than $1.2 Billion in Cash
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
